Ipsen's Stock Rises 2% Breaking Through the €163.5 Resistance
In early afternoon trading, the French biopharmaceutical company stands out in a sluggish Paris market. The stock continues its upward trend from recent weeks, boosted by an external growth operation in oncology announced earlier in the day. The stock subsequently breaks through a long-watched technical threshold.
Acquisition of Kartos Therapeutics Boosts Stock Performance During Session
Ipsen's stock is up 2.16% at €165.90 in early afternoon, while the SBF 120 is down 0.09% and the CAC 40 has fallen by 0.14%. The group announced on Monday the acquisition of American biotech Kartos Therapeutics for an initial amount of $450 million, a move that brings in navtemadlin, an advanced-stage drug candidate for myelofibrosis, a rare blood disease. This transaction strengthens the group's oncology pipeline, a strategic focus highlighted during the annual results announcement on May 28, 2026, which had identified the ability to address diseases with a high symptomatic burden. The stock's movement during the session follows a positive trend: up 6.01% for the week and 6.48% for the month, now accumulating nearly a 62% rise over the year.
The Stock Breaks Through Its €163.5 Resistance and Strengthens Its Upward Trend
Today's rebound breaks through a closely watched technical barrier: the stock has crossed the €163.5 resistance during the session and remains above it, at €165.90. The stock is now significantly above its three moving averages, with a gap of 5.57% over the MM20 (€157.15) and nearly 18% over the MM200 (€140.61), a configuration consistent with the underlying bullish trend. The RSI at 57 remains in the neutral zone, without any sign of excess. In terms of governance, Beech Tree obtained a waiver from the obligation to file a public offer in April, removing a point of uncertainty regarding the shareholders. The next technical level identified in the data is the resistance at €172.90, which is about 4% above the current price.
